Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

XNK Therapeutics

Request full access

Autologous natural killer cell-based cancer immunotherapies

Huddinge kommun, SwedenFounded 2013Biotech & Life Sciences

About XNK Therapeutics

XNK Therapeutics AB was a clinical-stage immunotherapy company founded in 2012 in Huddinge, Sweden, that focused on developing novel, autologous natural killer (NK) cell-based therapies for cancer treatment. The company, formerly known as Cell Protect Nordic Pharmaceuticals, developed a proprietary technology platform to expand and activate a patient's own NK cells to target cancers. Its operations spanned both hematological malignancies and solid tumor indications.

The company's lead drug candidate was CellProtect, and its product pipeline included ACP-001 and ISA-HC-NK. Their most advanced product, evencaleucel, was in phase II studies for treating multiple myeloma. Other programs in preclinical stages included XNK02 for acute myeloid leukemia (AML), XNK03 for bladder cancer, and XNK04 for hepatocellular carcinoma (liver cancer), often in collaboration with institutions like the MD Anderson Cancer Center and the Karolinska University Hospital. XNK Therapeutics operated its own in-house GMP facility.

Over its lifetime, the company secured funding through various rounds, including a grant of $110K in 2018, an angel round of $7.44M in 2021, and a Series B round of $13.9M on March 29, 2022, led by Flerie. Despite these efforts and receiving a scientific recommendation from the European Medicines Agency's (EMA) Committee for Advanced Therapies for its product Evencaleucel, the company faced financial difficulties. On April 9, 2024, XNK Therapeutics AB was declared bankrupt. Following the bankruptcy, the company's assets, including its GMP facility and intellectual property, were sold off.

Source: Dealroom company data

XNK Therapeutics in the Huddinge kommun ecosystem

Live from Dealroom

The XNK Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Vinnova
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇸🇪 Sweden · Huddinge kommun HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about XNK Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See XNK Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.